Activation of endothelin-1 receptor signaling pathways is associated with neointima formation, neoangiogenesis and irreversible pulmonary artery hypertension in patients with congenital heart disease

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1463-1471

  Huang, Haiqiong ^a   Zhang, Peng ^b   Wang, Zhen ^c   Tang, Feng ^d   Jiang, Zhen ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Congenital heart disease; Hemodynamic; Immunohistochemistry; Pulmonary artery hypertension

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLOOD CLOTTING FACTOR 8; CD3 ANTIBODY; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTERY INTIMA; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ARTERY; LUNG BIOPSY; MALE; NEOINTIMA; NEOVASCULARIZATION (PATHOLOGY); PULMONARY HYPERTENSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ACTINS; ADOLESCENT; ADULT; ANTIGENS, CD34; BIOPSY; CELL PROLIFERATION; CHINA; ENDOTHELIN-1; FACTOR VIII; FEMALE; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY ARTERY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUNICA INTIMA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79957723153     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0670     Document Type: Article

References (43)

1. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115: 1039-1050.
2. Toyoda T, Tateno S, Kawasoe Y, Shirai T, Shiina Y, Matsuo K, et al. Nationwide survey of care facilities for adults with congenital heart disease in Japan. Circ J 2009; 73: 1147-1150.
3. Lee JW, Song JM, Park JP, Lee JW, Kang DH, Song JK. Longterm prognosis of isolated significant tricuspid regurgitation. Circ J 2010; 74: 375-380.
4. Yoshimura N, Murakami H, Otaka S, Watanabe K, Watanabe S, Uese K, et al. Open heart operation in a child with congenital heart disease and hereditary spherocytosis. Circ J 2006; 70: 1655-1657.
5. Beghetti M, Tissot C. Pulmonary arterial hypertension in congenital heart diseases. Semin Respir Crit Care Med 2009; 30: 421-428.
6. Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res 2005; 57: 16R-20R.
7. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 2007; 5: 45-52.
8. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: Relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol 2001; 25: 104-110.
9. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569.
10. Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, et al. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 2004; 279: 27679-27687.
11. Chen D, Balyakina EV, Lawrence M, Christman BW, Meyrick B. Cyclooxygenase is regulated by ET-1 and MAPKs in peripheral lung microvascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 284: L614-L621.
12. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
13. Rice KM, Uddemarri S, Desai DH, Morrison RG, Harris R, Wright GL, et al. PGF2alpha-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN. Prostaglandins Other Lipid Mediat 2008; 85: 49-57.
14. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-621.
15. Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008; 129: 163-171.
16. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18: 533-547.
17. Soma S, Takahashi H, Muramatsu M, Oka M, Fukuchi Y. Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol 1999; 20: 620-630.
18. Rame JE. Pulmonary hypertension complicating congenital heart disease. Curr Cardiol Rep 2009; 11: 314-320.
19. Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv 2008; 71: 665-670.
20. Eicken A, Balling G, Gildein HP, Genz T, Kaemmerer H, Hess J. Transcatheter closure of a non-restrictive patent ductus arteriosus with an Amplatzer muscular ventricular septal defect occluder. Int J Cardiol 2007; 117: e40-e42.
21. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 2006; 110: 104-107.
22. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al; American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 14S-34S.
23. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43: 48S-55S.
24. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): The INOP Test Study Group. Circulation 2002; 106: I76-I81.
25. Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Widlitz AC, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95: 199-203.
26. Fried R, Falkovsky G, Newburger J, Gorchakova AI, Rabinovitch M, Gordonova MI, et al. Pulmonary arterial changes in patients with ventricular septal defects and severe pulmonary hypertension. Pediatr Cardiol 1986; 7: 147-154.
27. Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 1984; 69: 655-667.
28. Egito ES, Aiello VD, Bosisio IB, Lichtenfels AJ, Horta AL, Saldiva PH, et al. Vascular remodeling process in reversibility of pulmonary arterial hypertension secondary to congenital heart disease. Pathol Res Pract 2003; 199: 521-532.
29. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 1527-1538.
30. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/ Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707-2719.
31. Mitani Y, Ueda M, Komatsu R, Maruyama K, Nagai R, Matsumura M, et al. Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. Eur Respir J 2001; 17: 316-320.
32. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
33. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 2001; 195: 367-374.
34. Lévy M, Maurey C, Celermajer DS, Vouhé PR, Danel C, Bonnet D, et al. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007; 49: 803-810.
35. Castañares C, Redondo-Horcajo M, Magán-Marchal N, ten Dijke P, Lamas S, Rodríguez-Pascual F. Signaling by ALK5 mediates TGFbeta- induced ET-1 expression in endothelial cells: A role for migration and proliferation. J Cell Sci 2007; 120: 1256-1266.
36. Lutz J, Gorenflo M, Habighorst M, Vogel M, Lange PE, Hocher B. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 1999; 37: 423-428.
37. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000; 157: 1703-1711.
38. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005; 3: 309-314.
39. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-1250.
40. Richardson CJ, Schalm SS, Blenis J. PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol 2004; 15: 147-159.
41. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24: 200-216.
42. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
43. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004; 8: 551-564.